Put companies on watchlist
Cantourage Group SE
ISIN: DE000A3DSV01
WKN: A3DSV0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cantourage Group SE · ISIN: DE000A3DSV01 · EQS - Company News (34 News)
Country: Germany · Primary market: Germany · EQS NID: 1661039
20 June 2023 10:30AM

Canadian cannabis producer Green Karat enters German craft cannabis market in partnership with Cantourage


EQS-News: Cantourage Group SE / Key word(s): Market Launch
Canadian cannabis producer Green Karat enters German craft cannabis market in partnership with Cantourage

20.06.2023 / 10:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

Canadian cannabis producer Green Karat enters German craft cannabis market in partnership with Cantourage

Berlin, June 20, 2023 – Green Karat, a renowned Canadian company that specializes in the cultivation of Craft Cannabis, proudly announces its expansion into the European market. In collaboration with Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based medicinal products, Green Karat will soon make its high-quality cannabis flowers available to the German market. This expansion means a further improvement in the supply of high-quality craft cannabis for patients in Germany, who can already obtain medicinal cannabis as a prescription drug through pharmacies.

Green Karat is based in the province of Québec, Canada, and operates a state-of-the-art production facility of 1,160 square meters on the picturesque north coast of Montreal. With four specially equipped flower rooms and an annual cultivation capacity of 1,500 kg, Green Karat is ideally positioned for the cultivation of Craft Cannabis. Run by family and friends, the business is operated by a small but highly skilled team with many years of experience. Green Karat places great emphasis on growing small batches of premium cannabis flowers to ensure outstanding quality. The company is looking forward to entering into other international markets soon.

Kim Supple, Quality Manager of Green Karat, expressed her excitement about the new partnership: “Working with Cantourage will allow us to reach another milestone in the development of our company: entering the European market. We are proud to be able to provide patients in Germany with our unique cultivars. In doing so, we of course remain committed to our unwavering dedication to quality.”

“With Green Karat, we have gained an important partner whose products are already highly regarded in Canada. Collaborations of exactly this nature allow us to provide patients in this country with premium cannabis from the pharmacy,” commented Bernhard Retzer, Cantourage’s Global Director of Sales.

About Green Karat

Green Karat has been one of Health Canada’s licensed cannabis producers since May 2020. Founded on Montreal’s north shore, the family-owned business is dedicated to cultivating high-quality, handcrafted cannabis. In addition to motivation and dedication, it is the company’s unwavering determination that drives it to excel. Green Karat is aware of its social responsibility and its commitment to Health Canada. As such, the cultivation company always maintains the highest standards in the industry as set by Health Canada. The result of these constant efforts are small batches of certified premium cannabis.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2018 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com 

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.


Press contact Cantourage:
Frederick Steudemann
M +49 (0)30 4701 350-50
pr@cantourage.com


 


20.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Scale), Munich, Tradegate Exchange
EQS News ID: 1661039

 
End of News EQS News Service

1661039  20.06.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1661039&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Cantourage Group SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.